Correct chromosome segregation relies on the centromere-specific histone H3 isoform identified usually as CenH3, or as Cse4 in budding yeast. Cytological experiments have proven that Cse4 seems at extracentromeric loci in yeast cells poor for each the CAF-1 and HIR histone H3/H4 deposition complexes, per elevated nondisjunction in these double mutant cells. Right here, we examined molecular features of this Cse4 mislocalization. Genome-scale chromatin immunoprecipitation analyses demonstrated broader distribution of Cse4 exterior of centromeres in cac1Δ hir1Δ double mutant cells that lack each CAF-1 and HIR complexes than in both single mutant.
Nonetheless, cytological localization confirmed that the important inside kinetochore element Mif2 (CENP-C) was not recruited to extracentromeric Cse4 in cac1Δ hir1Δ double mutant cells. We additionally noticed that rpb1-1 mutants displayed a modestly elevated Cse4 half-life at nonpermissive temperatures, suggesting that turnover of Cse4 is partially depending on Pol II transcription. We used genome-scale assays to exhibit that the CAF-1 and HIR complexes independently stimulate replication-independent histone H3 turnover charges. We talk about methods through which altered histone change kinetics might have an effect on eviction of Cse4 from noncentromeric loci.
The leucine-rich repeat (LRR) protein, CaLRR1, interacts with the hypersensitive induced response (<em>HIR</em>) protein, Ca<em>HIR</em>1, and suppresses cell demise induced by the Ca<em>HIR</em>1 protein.
Leucine-rich repeat proteins (LRRs) operate in a lot of sign transduction pathways by way of protein-protein interactions. The gene encoding a small protein of pepper, CaLRR1, is particularly induced upon pathogen problem and therapy with pathogen-associated molecular patterns (PAMPs). We recognized a pepper hypersensitive induced response (CaHIR1) protein that interacts with the LRR area of the CaLRR1 protein utilizing yeast two-hybrid screening. Ectopic expression of the pepper CaHIR1 gene induces cell demise in tobacco and Arabidopsis, indicating that the CaHIR1 protein could also be a constructive regulator of HR-like cell demise.
As a result of transformation may be very troublesome in pepper vegetation, we over-expressed CaLRR1 and CaHIR1 in Arabidopsis to find out mobile capabilities of the 2 genes. The over-expression of the CaHIR1 gene, however not the CaLRR1 gene, in transgenic Arabidopsis confers illness resistance in response to Pseudomonas syringae an infection, accompanied by the sturdy expression of PR genes, the buildup of each salicylic acid and H(2)O(2), and Okay(+) efflux in plant cells.
In Arabidopsis and tobacco vegetation over-expressing each CaHIR1 and CaLRR1, the CaLRR1 protein suppresses not solely CaHIR1-induced cell demise, but in addition PR gene expression elicited by CaHIR1 by way of its affiliation with HIR protein. We suggest that the CaLRR1 protein capabilities as a novel damaging regulator of CaHIR1-mediated cell demise responses in vegetation.
FIP2 and Rip11 specify Rab11a-mediated mobile distribution of GLUT4 and FAT/CD36 in H9c2-hIR cells.
Rab11a has been proven to be concerned in numerous vesicle trafficking processes. To additional outline the purposeful position of Rab11a in vesicle motion we knocked down gene expression of Rab11a and two of its effectors, Rip11 and FIP2, in H9c2-hIR cells and measured the cell floor abundance of GLUT4myc and FAT/CD36. We noticed that by flattening Rab11a, each GLUT4myc and FAT/CD36 abundance on the plasma membrane had been considerably elevated. Within the case of GLUT4myc, the in vitro knockdown of FIP2 additionally elevated the cell floor abundance of GLUT4myc.
Knockdown of each FIP2 and Rip11 improve the abundance of FAT/CD36 on the plasma membrane. Stimulated translocation of GLUT4myc and FAT/CD36 is just not altered after gene knockdown of Rab11a. These knowledge subsequently present that (i) Rab11a regulates cell floor abundance of each GLUT4 and FAT/CD36 and that (ii) each Rab11a-dependent processes are in another way regulated by Rab11a effector proteins.
Replication-independent histone deposition by the HIR advanced and Asf1.
The orderly deposition of histones onto DNA is mediated by conserved meeting complexes, together with chromatin meeting factor-1 (CAF-1) and the Hir proteins . CAF-1 and the Hir proteins function in distinct however functionally overlapping histone deposition pathways in vivo . The Hir proteins and CAF-1 share a typical associate, the extremely conserved histone H3/H4 binding protein Asf1, which binds the center subunit of CAF-1 in addition to to Hir proteins . Asf1 binds to newly synthesized histones H3/H4 , and this advanced stimulates histone deposition by CAF-1 .
HIRIP3 Polyclonal Antibody |
|||
| 30792-50ul | SAB | 50ul | EUR 224.4 |
Polyclonal HIRIP3 Antibody |
|||
| APR02968G | Leading Biology | 0.05ml | EUR 580.8 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human HIRIP3 . This antibody is tested and proven to work in the following applications: |
|||
Anti-HIRIP3 antibody |
|||
| PAab03871 | Lifescience Market | 100 ug | EUR 494.4 |
anti- HIRIP3 antibody |
|||
| FNab03871 | FN Test | 100µg | EUR 702 |
|
Description: Antibody raised against HIRIP3 |
|||
Anti-HIRIP3 antibody |
|||
| STJ29094 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: The HIRA protein shares sequence similarity with Hir1p and Hir2p, the two corepressors of histone gene transcription characterized in the yeast, Saccharomyces cerevisiae. The structural features of the HIRA protein suggest that it may function as part of a multiprotein complex. Several cDNAs encoding HIRA-interacting proteins, or HIRIPs, have been identified. In vitro, the protein encoded by this gene binds HIRA, as well as H2B and H3 core histones, indicating that a complex containing HIRA-HIRIP3 could function in some aspects of chromatin and histone metabolism. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. |
|||
HIRIP3 siRNA |
|||
| 20-abx919397 | Abbexa |
|
|
HIRIP3 siRNA |
|||
| 20-abx919398 | Abbexa |
|
|
anti-HIRIP3 |
|||
| YF-PA15655 | Abfrontier | 50 ul | EUR 435.6 |
|
Description: Mouse polyclonal to HIRIP3 |
|||
anti-HIRIP3 |
|||
| YF-PA15656 | Abfrontier | 50 ug | EUR 435.6 |
|
Description: Mouse polyclonal to HIRIP3 |
|||
pOTB7-HIRIP3 |
|||
| PVT18716 | Lifescience Market | 2 ug | EUR 277.2 |
Polyclonal HIRIP3 Antibody (Center) |
|||
| APR16639G | Leading Biology | 0.1ml | EUR 580.8 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human HIRIP3 (Center). This antibody is tested and proven to work in the following applications: |
|||
HIRIP3 Polyclonal Conjugated Antibody |
|||
| C30792 | SAB | 100ul | EUR 476.4 |
HIRIP3 Polyclonal Conjugated Antibody |
|||
| C31854 | SAB | 100ul | EUR 476.4 |
HIRIP3 Blocking Peptide |
|||
| 33R-8235 | Fitzgerald | 100 ug | EUR 216 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of HIRIP3 antibody, catalog no. 70R-2185 |
|||
HIRIP3 Rabbit pAb |
|||
| A7014-100ul | Abclonal | 100 ul | EUR 369.6 |
HIRIP3 Rabbit pAb |
|||
| A7014-200ul | Abclonal | 200 ul | EUR 550.8 |
HIRIP3 Rabbit pAb |
|||
| A7014-20ul | Abclonal | 20 ul | EUR 219.6 |
HIRIP3 Rabbit pAb |
|||
| A7014-50ul | Abclonal | 50 ul | EUR 267.6 |
HIRIP3 cloning plasmid |
|||
| CSB-CL883612HU-10ug | Cusabio | 10ug | EUR 451.2 |
|
Description: A cloning plasmid for the HIRIP3 gene. |
|||
Anti-HIRIP3 (3B3) |
|||
| YF-MA11069 | Abfrontier | 100 ug | EUR 435.6 |
|
Description: Mouse monoclonal to HIRIP3 |
|||
Human HIRIP3 shRNA Plasmid |
|||
| 20-abx955558 | Abbexa |
|
|
Mouse HIRIP3 shRNA Plasmid |
|||
| 20-abx982088 | Abbexa |
|
|
HIRIP3 ELISA KIT|Human |
|||
| EF010125 | Lifescience Market | 96 Tests | EUR 826.8 |
HIRIP3 Recombinant Protein (Human) |
|||
| RP014686 | ABM | 100 ug | Ask for price |
HIRIP3 Recombinant Protein (Rat) |
|||
| RP204605 | ABM | 100 ug | Ask for price |
HIRIP3 Recombinant Protein (Mouse) |
|||
| RP141530 | ABM | 100 ug | Ask for price |
HIRA-Interacting Protein 3 (HIRIP3) Antibody |
|||
| abx037953-100ug | Abbexa | 100 ug | EUR 469.2 |
HIRA-Interacting Protein 3 (HIRIP3) Antibody |
|||
| 20-abx005315 | Abbexa |
|
|
HIRA-Interacting Protein 3 (HIRIP3) Antibody |
|||
| 20-abx113016 | Abbexa |
|
|
HIRA-Interacting Protein 3 (HIRIP3) Antibody |
|||
| abx030421-400ul | Abbexa | 400 ul | EUR 627.6 |
HIRA-Interacting Protein 3 (HIRIP3) Antibody |
|||
| abx030421-80l | Abbexa | 80 µl | EUR 343.2 |
HIRA-Interacting Protein 3 (HIRIP3) Antibody |
|||
| abx233871-100ug | Abbexa | 100 ug | EUR 661.2 |
Hirip3 ORF Vector (Rat) (pORF) |
|||
| ORF068203 | ABM | 1.0 ug DNA | EUR 607.2 |
HIRIP3 ORF Vector (Human) (pORF) |
|||
| ORF004896 | ABM | 1.0 ug DNA | EUR 114 |
Hirip3 ORF Vector (Mouse) (pORF) |
|||
| ORF047178 | ABM | 1.0 ug DNA | EUR 607.2 |
Hirip3 sgRNA CRISPR Lentivector set (Rat) |
|||
| K7156001 | ABM | 3 x 1.0 ug | EUR 406.8 |
HIRIP3 sgRNA CRISPR Lentivector set (Human) |
|||
| K0953201 | ABM | 3 x 1.0 ug | EUR 406.8 |
Hirip3 sgRNA CRISPR Lentivector set (Mouse) |
|||
| K4629701 | ABM | 3 x 1.0 ug | EUR 406.8 |
Hirip3 sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K7156002 | ABM | 1.0 ug DNA | EUR 184.8 |
Hirip3 sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K7156003 | ABM | 1.0 ug DNA | EUR 184.8 |
Hirip3 sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K7156004 | ABM | 1.0 ug DNA | EUR 184.8 |
HIRIP3 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K0953202 | ABM | 1.0 ug DNA | EUR 184.8 |
HIRIP3 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K0953203 | ABM | 1.0 ug DNA | EUR 184.8 |
HIRIP3 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K0953204 | ABM | 1.0 ug DNA | EUR 184.8 |
Hirip3 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K4629702 | ABM | 1.0 ug DNA | EUR 184.8 |
Hirip3 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K4629703 | ABM | 1.0 ug DNA | EUR 184.8 |
Hirip3 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K4629704 | ABM | 1.0 ug DNA | EUR 184.8 |
HIRIP3 Protein Vector (Human) (pPB-C-His) |
|||
| PV019581 | ABM | 500 ng | EUR 394.8 |
HIRIP3 Protein Vector (Human) (pPB-N-His) |
|||
| PV019582 | ABM | 500 ng | EUR 394.8 |
HIRIP3 Protein Vector (Human) (pPM-C-HA) |
|||
| PV019583 | ABM | 500 ng | EUR 394.8 |
HIRIP3 Protein Vector (Human) (pPM-C-His) |
|||
| PV019584 | ABM | 500 ng | EUR 394.8 |
HIRIP3 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV188710 | ABM | 500 ng | EUR 723.6 |
HIRIP3 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV188711 | ABM | 500 ng | EUR 723.6 |
HIRIP3 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV188712 | ABM | 500 ng | EUR 723.6 |
HIRIP3 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV188713 | ABM | 500 ng | EUR 723.6 |
HIRIP3 Protein Vector (Rat) (pPB-C-His) |
|||
| PV272810 | ABM | 500 ng | EUR 723.6 |
HIRIP3 Protein Vector (Rat) (pPB-N-His) |
|||
| PV272811 | ABM | 500 ng | EUR 723.6 |
HIRIP3 Protein Vector (Rat) (pPM-C-HA) |
|||
| PV272812 | ABM | 500 ng | EUR 723.6 |
HIRIP3 Protein Vector (Rat) (pPM-C-His) |
|||
| PV272813 | ABM | 500 ng | EUR 723.6 |
Hirip3 3'UTR GFP Stable Cell Line |
|||
| TU255784 | ABM | 1.0 ml | Ask for price |
HIRIP3 3'UTR GFP Stable Cell Line |
|||
| TU059797 | ABM | 1.0 ml | EUR 1672.8 |
Hirip3 3'UTR Luciferase Stable Cell Line |
|||
| TU205784 | ABM | 1.0 ml | Ask for price |
Hirip3 3'UTR Luciferase Stable Cell Line |
|||
| TU109519 | ABM | 1.0 ml | Ask for price |
Hirip3 3'UTR GFP Stable Cell Line |
|||
| TU159519 | ABM | 1.0 ml | Ask for price |
HIRIP3 3'UTR Luciferase Stable Cell Line |
|||
| TU009797 | ABM | 1.0 ml | EUR 1672.8 |
Human HIRA-Interacting Protein 3 (HIRIP3) ELISA Kit |
|||
| abx387793-96tests | Abbexa | 96 tests | EUR 1093.2 |
Human HIRA- interacting protein 3, HIRIP3 ELISA KIT |
|||
| ELI-38603h | Lifescience Market | 96 Tests | EUR 988.8 |
HIRIP3 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV627643 | ABM | 1.0 ug DNA | EUR 818.4 |
HIRIP3 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV627647 | ABM | 1.0 ug DNA | EUR 818.4 |
HIRIP3 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV627648 | ABM | 1.0 ug DNA | EUR 818.4 |
Mouse HIRA- interacting protein 3, Hirip3 ELISA KIT |
|||
| ELI-14456m | Lifescience Market | 96 Tests | EUR 1038 |
Hirip3 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|||
| K7156005 | ABM | 3 x 1.0 ug | EUR 451.2 |
HIRIP3 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K0953205 | ABM | 3 x 1.0 ug | EUR 451.2 |
Hirip3 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|||
| K4629705 | ABM | 3 x 1.0 ug | EUR 451.2 |
HIRIP3 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV627644 | ABM | 1.0 ug DNA | EUR 818.4 |
HIRIP3 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV627645 | ABM | 1.0 ug DNA | EUR 888 |
HIRIP3 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV627646 | ABM | 1.0 ug DNA | EUR 888 |
Hirip3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|||
| K7156006 | ABM | 1.0 ug DNA | EUR 200.4 |
Hirip3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|||
| K7156007 | ABM | 1.0 ug DNA | EUR 200.4 |
Hirip3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|||
| K7156008 | ABM | 1.0 ug DNA | EUR 200.4 |
HIRIP3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K0953206 | ABM | 1.0 ug DNA | EUR 200.4 |
HIRIP3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K0953207 | ABM | 1.0 ug DNA | EUR 200.4 |
HIRIP3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K0953208 | ABM | 1.0 ug DNA | EUR 200.4 |
Hirip3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
|||
| K4629706 | ABM | 1.0 ug DNA | EUR 200.4 |
Hirip3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
|||
| K4629707 | ABM | 1.0 ug DNA | EUR 200.4 |
Hirip3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
|||
| K4629708 | ABM | 1.0 ug DNA | EUR 200.4 |
CD11b Antibody Antibody |
|||
| ABD2911 | Lifescience Market | 100 ug | EUR 525.6 |
ASAP1 antibody Antibody |
|||
| DF8746 | Affbiotech | 200ul | EUR 420 |
anti- Antibody^Polyclonal antibody control antibody |
|||
| LSMab09882 | Lifescience Market | 100 ug | EUR 525.6 |
ARHGDIA Antibody / RHOGDI Antibody |
|||
| F54788-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 165 |
ARHGDIA Antibody / RHOGDI Antibody |
|||
| F54788-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 379 |
Antibody |
|||
| A1360-500 | Biovision | Ask for price | |
Anti-Glycolipid Antibody (AGA) Antibody |
|||
| 20-abx004855 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx008109 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx123734 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx014333 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| abx033330-400ul | Abbexa | 400 ul | EUR 627.6 |
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| abx033330-80l | Abbexa | 80 µl | EUR 343.2 |
Anti-Glycolipid Antibody (AGA) Antibody |
|||
| abx036399-100ug | Abbexa | 100 ug | EUR 469.2 |
Anti-Glycoprotein Antibody (GP) Antibody |
|||
| 20-abx319900 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
| 20-abx319901 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
| 20-abx319905 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
| 20-abx319913 | Abbexa |
|
|
Anti-Glycolipid Antibody (AGA) Antibody |
|||
| abx230204-100ug | Abbexa | 100 ug | EUR 577.2 |
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx324434 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| 20-abx311665 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
| abx234901-100ug | Abbexa | 100 ug | EUR 661.2 |
Anti-Anti-SEPT6 antibody antibody |
|||
| STJ11100949 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined. |
|||
Anti-Anti-SEPT9 Antibody antibody |
|||
| STJ111369 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described. |
|||
Anti-Anti-SEPT11 Antibody antibody |
|||
| STJ111530 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT4 Antibody antibody |
|||
| STJ112276 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer. |
|||
Anti-Anti-MARCH9 Antibody antibody |
|||
| STJ112609 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT11 Antibody antibody |
|||
| STJ113941 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT11 Antibody antibody |
|||
| STJ114081 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT5 Antibody antibody |
|||
| STJ114819 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
|||
Anti-Anti-MARCH8 Antibody antibody |
|||
| STJ114828 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT7 Antibody antibody |
|||
| STJ116214 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
|||
Anti-Anti-SEPT8 Antibody antibody |
|||
| STJ117206 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-Anti-SEPT12 Antibody antibody |
|||
| STJ117759 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene encodes a guanine-nucleotide binding protein and member of the septin family of cytoskeletal GTPases. Septins play important roles in cytokinesis, exocytosis, embryonic development, and membrane dynamics. Multiple transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-Anti-MARCH6 Antibody antibody |
|||
| STJ118549 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-MARCH6 Antibody antibody |
|||
| STJ118550 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-MARCH7 Antibody antibody |
|||
| STJ118752 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT3 Antibody antibody |
|||
| STJ118990 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT2 Antibody antibody |
|||
| STJ28365 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT7 Antibody antibody |
|||
| STJ28963 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
|||
Anti-Anti-SEPT2 Antibody antibody |
|||
| STJ25475 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT5 Antibody antibody |
|||
| STJ25477 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
|||
Anti-Anti-SEPT8 Antibody antibody |
|||
| STJ25479 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-Anti-SEPT1 antibody antibody |
|||
| STJ119580 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis and the maintenance of cellular morphology. This gene encodes a protein that can form homo- and heterooligomeric filaments, and may contribute to the formation of neurofibrillary tangles in Alzheimer's disease. Alternatively spliced transcript variants have been found but the full-length nature of these variants has not been determined. [provided by RefSeq, Dec 2012] |
|||
CLCN5 Antibody / CIC-5 antibody |
|||
| RQ6462 | NSJ Bioreagents | 100ug | EUR 419 |
|
Description: The CLCN5 gene encodes the chloride channel Cl-/H+ exchanger ClC-5. This gene encodes a member of the ClC family of chloride ion channels and ion transporters. The encoded protein is primarily localized to endosomal membranes and may function to facilitate albumin uptake by the renal proximal tubule. Mutations in this gene have been found in Dent disease and renal tubular disorders complicated by nephrolithiasis. Alternatively spliced transcript variants have been found for this gene. |
|||
Cytokeratin 7 antibody-Cytoskeleton Marker Antibody |
|||
| 48169-100ul | SAB | 100ul | EUR 399.6 |
Cytokeratin 7 antibody-Cytoskeleton Marker Antibody |
|||
| 48169-50ul | SAB | 50ul | EUR 286.8 |
Anti CD22 Antibody: CD22 Monoclonal Antibody |
|||
| 065-A-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: anti-CD22 monoclonal antibody |
|||
Anti CD22 Antibody: CD22 Monoclonal Antibody |
|||
| 065-A-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: anti-CD22 monoclonal antibody |
|||
Antibody Pair to ApoA-V antibody |
|||
| 10R-1876 | Fitzgerald | 100 ul | EUR 781.2 |
|
Description: Mouse monoclonal Antibody Pair to ApoA-V antibody |
|||
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
| 20-abx103034 | Abbexa |
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
| 20-abx103035 | Abbexa |
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
| 20-abx103036 | Abbexa |
|
|
Hepatitis C Virus Antibody (HCV) Antibody |
|||
| abx023924-1mg | Abbexa | 1 mg | EUR 1446 |
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
| 20-abx319902 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
| 20-abx319903 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
| 20-abx319904 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
| 20-abx319906 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
| 20-abx319907 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
| 20-abx319908 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
| 20-abx319914 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
| 20-abx319915 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
| 20-abx319916 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
| 20-abx319929 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
| 20-abx319930 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
| 20-abx319931 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody (HRP) |
|||
| 20-abx311666 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody (FITC) |
|||
| 20-abx311667 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody (Biotin) |
|||
| 20-abx311668 | Abbexa |
|
|
Anti-Glycoprotein 210 Antibody (gp210) Antibody |
|||
| abx233571-100ug | Abbexa | 100 ug | EUR 577.2 |
Anti Deoxyribonucleic Acid Antibody (DNA) Antibody |
|||
| abx411057-50ug | Abbexa | 50 ug | EUR 710.4 |
Monoclonal NGF/proNGF Neutralizing Antibody Antibody |
|||
| AMM06679G | Leading Biology | 0.05mg | EUR 633.6 |
|
Description: A Monoclonal antibody against Human NGF/proNGF Neutralizing. The antibodies are raised in Mouse. This antibody is applicable in E |
|||
Goat anti- human Antibody^Polyclonal antibody |
|||
| LSMab09896 | Lifescience Market | 100 ug | EUR 525.6 |
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D | Stressmarq | 0.1mg | EUR 424.8 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is unconjugated. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A390 | Stressmarq | 0.1mg | EUR 481.2 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 390. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A488 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 488. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A565 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 565. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A594 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 594. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A633 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 633. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A655 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 655. |
|||
Antibody for Human alpha Tubulin Antibody |
|||
| SPC-692D-A680 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 680. |
|||
In yeast, Asf1 is required for the contribution of the Hir proteins to gene silencing . Right here, we exhibit that Hir1, Hir2, Hir3, and Hpc2 comprise the HIR advanced, which copurifies with the histone deposition protein Asf1. Collectively, the HIR advanced and Asf1 deposit histones onto DNA in a replication-independent method. Histone deposition by the HIR advanced and Asf1 is impaired by a mutation in Asf1 that inhibits HIR binding. These knowledge point out that the HIR advanced and Asf1 proteins operate collectively as a conserved eukaryotic pathway for histone alternative all through the cell cycle.